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The immune checkpoints, CTLA-4 and PD-1, are nega-
tive regulators of T cell activation and are inducers of
FoxP3+ Tregs. Monoclonal antibody therapy to each has
demonstrated tumor regression in clinical trials and potent
therapeutic synergy has been observed when used in
combination. MicroRNAs (miRs) have been shown to
modulate gene transcripts involved in tumorigenesis and
can target tumor-mediated immune suppression. On the
basis of differential miRNA gene expression libraries from
glioblastoma patients, miR-138 was identified as a top
down regulated candidate. On glioma tumor microarrays,
miR-138 expression is heterogeneous among the various
grades and pathologies. Target binding algorithms pre-
dicted that miR-138 could bind CTLA-4 and PD-1. Trans-
fection of human CD4+ T cells with miR-138 suppressed
CTLA-4-, PD-1-, and FoxP3- expression in vitro. Treat-
ment of established subcutaneous GL261 murine glioma
cells in immune competent C57BL/6 mice with miR-138
or scramble control administered intravenously demon-
strated that gliomas started to shrink as soon as miR-138
was administered. Moreover, the gliomas continued to
regress even after miR-138 treatment was discontinued. In
contrast, tumors kept growing aggressively in scramble
miRNA-treated and untreated tumor-bearing mice groups.
Furthermore, in C57BL/6 mice with established intracer-
ebral GL261 treated with i.v. administered miR-138, med-
ian survival was 33.5 days relative to mice treated with
scramble control with a median survival of 23.5 days
(P=0.011). Intravenous treatment of mice with established
intracerebral gliomas with miR-138 relative to the scram-
ble control reduced the relative incidence of Tregs by 51%
(P=0.03) within the glioma microenvironment. Formula-
tion equivalency studies in vivo indicate that DOTAP
causes rapid translocation of miRNAs into the peripheral
blood compartment indicating that miR-138 may have
rapid translational potential as a novel immunotherapeutic
agent for neoplasms.
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